A recent paper addresses the challenges and explores opportunities to stimulate repurposing of FDA-approved drugs for Alzheimer's, Parkinson's and related diseases.

A new peer-reviewed publication from the Alzheimer's Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug Administration (FDA)-approved drugs for the treatment of neurodegenerative diseases.

The paper, published in the Annals of Clinical and Translational Neurology, was produced in collaboration with experts from these sectors and highlights the unique challenges and lack of commercial incentives for testing approved drugs in new disease indications, like Alzheimer's or Parkinson's disease, where they might be beneficial.

Source:  Digital Journal

Links

http://www.digitaljournal.com/pr/2018907

יולי 1, 2014